Interesting things Don laid out. Seems like Zenith is definitely the bright star, and deservedly so I guess with the partners, funding, and early results.

As far as funding for RVX, fugeddaboudit. But they aren't giving up on the potential. Two paths forward it seems: 1) Middle East Covid deals under EUA to get trials, utilization, and revenues, 2) Selling off a portion of Zenith's future RVX royalties for cash now for BoM2 funding (not sure how exactly this works, but okay).

I do think it is interesting the number of huge revenue patents sunsetting in the next three years. Multiple companies with RVX experience/partnering. For a long time I thought our 8 year lead was a positive, but it may be better if there are other epigenetics companies knocking at the door also, more legitimacy and acceptance. 

Another interesting disclosure is that Don is NOT being paid now. Many would say rightfully so if true, but that could also be some motivation for him to get something done. He sure made a point of that, maybe he reads our board?? :)

I got the impression that Don thinks he is close to some good deals, for advancing the companies. 

Whatever happens, I am glad that they are getting more creative, and trying to utilize more of their tools and options.

Soooooo ... potential bulk Covid sales in the Middle East in 2024, and BoM2 Interim Report in 2025 ... looks like best case for ABL, at this time and current projection. Barring a BP swoop & scoop.